EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma

Antoni Ribas iD, Caroline Robert iD, Dirk Schadendorf iD, Georgina V Long iD, Hussein Tawbi iD, Keith Flaherty iD, Paolo A Ascierto iD, Paul Nathan iD, Piotr Rutkowski iD, Oleg V Leonov iD, Paul Lorigan iD, Sorilla Prey iD und 13 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00528 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Antoni Ribas und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Melanoma, Proto-Oncogene Proteins B-raf. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692 ) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600–mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This final analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months). The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]). The safety findings were consistent with the known safety profile for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone in patients with BRAF V600–mutant metastatic melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsMelanomaProto-Oncogene Proteins B-rafSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedImidazolesMutationOximesProgression-Free SurvivalPyridonesPyrimidinones

Substanzen

Antibodies, Monoclonal, HumanizedBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesspartalizumabtrametinib

Autor:innen und Institutionen

  • University of California Los Angeles, Los Angeles, CA.
  • Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.
  • Université Paris-Saclay, Gustave Roussy, Inserm, Biomarqueurs Prédicteurs et nouvelles Stratégies Moléculaires en Thérapeutique Anticancéreuse, Villejuif, France.
  • University Hospital Essen, National Center for Tumor Diseases (NCT-West), German Cancer Consortium, Both Campus Essen, and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
  • The Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Antoni Ribas, Caroline Robert, Dirk Schadendorf, Georgina V Long, Hussein Tawbi, Keith Flaherty, Paolo A Ascierto, Paul Nathan, Piotr Rutkowski, Oleg V Leonov, Paul Lorigan, Sorilla Prey, Maristella Saponara, Daniil Stroyakovskiy, Celeste Lebbe, Michele Maio, Pamela Salman Boghikian, Ralf Gutzmer, Mark Russo, Reinhard Dummer

Zitieren

APA

Ribas, A., Robert, C., Schadendorf, D., Long, G. V., Tawbi, H., Flaherty, K., Ascierto, P. A., Nathan, P., Rutkowski, P., Leonov, O. V., Lorigan, P., Prey, S., Saponara, M., Arance, A., Gaudy-Marqueste, C., Stroyakovskiy, D., Lebbe, C., Maio, M., Del Vecchio, M., …, & Dummer, R. (2026). COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00528

Vancouver

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, et al. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00528

BibTeX
@article{Ribas2026,
  author = {Ribas, Antoni and Robert, Caroline and Schadendorf, Dirk and Long, Georgina V and Tawbi, Hussein and Flaherty, Keith and Ascierto, Paolo A and Nathan, Paul and Rutkowski, Piotr and Leonov, Oleg V and Lorigan, Paul and Prey, Sorilla and Saponara, Maristella and Arance, Ana and Gaudy-Marqueste, Caroline and Stroyakovskiy, Daniil and Lebbe, Celeste and Maio, Michele and Del Vecchio, Michele and Boghikian, Pamela Salman and Gutzmer, Ralf and Depenni, Roberta and Miskic, Marina and Russo, Mark and Dummer, Reinhard},
  title = {COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00528}
}
Kostenlos starten →